Aims: the presented study is aimed at the evaluation of correlation of free light chains serum levels -kappa, lambda and their relation (K/L ratio) and serum levels of selected biological markers in a group of patients with multiple myeloma examined at the time of the diagnosis.
INTRODUCTION
Multiple myeloma (MM) is a malignant hematological disease characterised by the uncontrolled proliferation and accumulation of neoplastically transformed plasma cells, production of monoclonal immunoglobulin (MIG) detectable in the serum and/or urine and various degrees of organ involvement (hypercalcemia, renal insuffi ciency, osteolytic bone lesions or osteoporosis, anemia and immunodefi ciency) 1, 2 . Apart from the complete molecule of monoclonal immunoglobulin, the plasma cells also produce single free light chains (FLC) which are not fi xed to the MIG molecule 3 . In the last few years, the assessment of free light chain serum levels has become an irreplaceable part of the examination algorithm in diagnostics, screening and evaluation of treatment response not only in patients with multiple myeloma but also in other malignant or potentially malignant monoclonal gammopathies [4] [5] [6] . The bone marrow microenvironment in relation to the pathological plasmacellular infi ltration is characterised by a very large system of intercellular and cytokine interactions among the stromal cells of bone marrow, bone elements and tumour cells themselves, in close relation to their own biological qualities of the disease 7 . Some unusual biochemical parameters appear to be very promising as possible future markers not only in the neoplastic transformation of potential malignant monoclonal gammopathy of undetermined signifi cance (MGUS) and its diff erentiation from the early stage MM but also as markers of advanced stage, progression and monitoring of treatment response in patients with multiple myeloma [8] [9] [10] . The aim of this study was to determine the relation of FLC serum levels to 12 selected less usual biological parameters in patients with multiple myeloma who were examined at the time of diagnosis.
MATERIALS AND METHODS
The sample studied included 102 patients examined at the time of diagnosis and who fulfi led the SWOG and IMWG criteria for multiple myeloma diagnosis 11 . The age range was 43-82, median 63 years, men and women ratio 1:1.04. Immunochemical type IgG was found in 58 % (n = 60), IgA 22 % (n = 22), Bence -Jones 17 % (n = 17), IgD 1 % (n = 1) and nonsecretoric type 2 % (n = 2). The kappa light chain secretion was found in 68 % (n=69) and lambda secretion in 32 % (n = 33) of patients. With the use of Durie-Salmon staging system there 12 % (n = 12) of patients were in stage I, 28 % (n = 29) in stage II and 60 % (n = 61) in stage III. The A substage (creatinine under 177 μmol/l) was found in 75 % of patients 12 . Using the International Prognostic Index (IPI) staging system 12 % (n = 12) of patients were in the 1st stage, 22 % (n = 22) in the 2nd stage and 66 % (n = 68) in the 3rd stage 13 . Serum levels of free light chains were set by the Freelite 3 ). Serum levels were determined by the following methods: β 2 microglobulin (β 2 m) by the radioimmunoanalysis method (RIA, standard range 0-2.5 mg/l), tymidine kinase (TK) by radioenzymatic method (REA, 0-6 IU/l), intercellular C-terminal telopeptide collagen-I (ICTP, m: 2.1-5.0, w: 2.1-5.6 μg/l) and N-terminal peptide procollagen-I (PINP, m: 21-78, w: 19-102 μg/l) by RIA method; vascular cell adhesive molecule-1 (sVCAM, 395-714 ng/ml), intercellular cell adhesive molecule-1 (sICAM, 269-691 ng/ml), solubile form of IL-6R (sIL-6R, 10-90 ng/ml) and solubile osteoprotegerine (sOPG, 3.7-4.4 μmol/l) by enzymeimmunoassay method; hepatocyte growth factor (sHGF, 671-1992 pg/ml), vascular endothelial growth factor (sVEGF, 62-707 pg/ml), syndecan-1/sCD138 (sSyn-1, 37-123 ng/ml) and Fas antigen (sFas 4792-1750 pg/ml) were determined by a quantitative sandwich enzymatic immunoassay method. For statistical evaluation the Spearman Rank Correlation Coeffi cient test was used. Kappa and lambda secretion, respectively kappa and lambda groups were assessed separately due to the reciprocal relation of serum levels and K/L ratio of free chains.
RESULTS
Abnormal serum levels of free light chains were recorded in 92 % of patients and, a pathological K/L ratio was found in 91 % cases. Abnormal β 2 m levels were recorded in 95.1 %, in TK in 58.8 %, sIL-6R in 68.6 %, sVCAM in 74 %, sICAM in 32.6 %, ICTP in 72.7 %, PINP in 21 %; abnormal levels (under and above standard interval) were recorded in case of sOPG in 97. 
DISCUSSION
The results show the mutual relation of serum levels of FLC, K/L ratio and selected untraditional markers of multiple myeloma. The abnormal percentage of serum free light chain levels and K/L ratio for the analysed group approximately corresponds to previously published studies which have reported comparable pathological percentages of FLC even if there was a higher percentage in the case of the K/L ratio than FLC levels themselves in most studies 4, 14, 15 . The correlation of FLC serum levels, K/L ratio and β 2 m levels not only results from the biological qualities of both parameters (level increase in case of renal insufi ciency, polymerization), but also both parameters are markers of the size of the tumour mass. The interval levels of β 2 m, the most important prognostic factor in multiple myeloma, are the new staging systems components -International Prognostic Index (IPI), South-West Oncology Group (SWOG) (ref. 12, 16 ); there was a correlation of these system stages and FLC levels, also the combination of IPI system and serum levels of FLC and K/L ratio appears to be very promising prognostic marker [17] [18] [19] [20] . The relation of FLC and serum tymidinekinase as proliferation markers and as tumour mass markers is explainable as well; an association was found of FLC serum levels and OLOMOUC staging system phases in which β 2 m and TK serum levels were used [21] [22] [23] . The detected relation of the bone metabolism parameters ICTP, PINP and FLC levels can also be explained by the association of these markers to the stage of bone involvement and also to the progress and prognosis of the disease 24, 25 . Detected relation of FLC, K/L ratio serum levels and Syndecan-1 confi rms the unique position of this less usual parameter. Syndecan-1 is a proteoglycan released from the surface of viable malignant plasma cells, mainly concerned with the proliferation process, apoptosis of tumour and also bone cells and relating bone involvement; infl uences the cytokine net in direct and indirect way in conditions of 63 The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma the bone marrow microenvironment. It is considered to be one of the most important molecules in the multiple myeloma pathobiology 26 . Syndecan-1 appears to be a new important prognostic marker, also a possible parameter for discernment of monoclonal gammopathy of undetermined signifi cance and multiple myeloma 8, 9, [27] [28] [29] . Detected correlation of FLC, K/L ratio and sFas levels is now more of the academical meaning which would be observed. Solubile Fas antigen is a part of antiapoptotic mechanisms participating in the immortality of tumour cell line 30 .
CONCLUSIONS
The results confi rm the relation of serum levels of free light chain kappa, resp. lambda and K/L ratio and several less usual parameters in multiple myeloma. The study confi rmed the association with tumour mass, biolocal qualities of myeloma cells, parameters of bone metabolism, myeloma bone disease and the bone marrow microenvironment itself. The conclusions of the study give source materials for use of less usual markers for distinguishing monoclonal gammopathy of undetermined signifi cance from multiple myeloma and for evaluation of progress and treatment response in patients with MM. Kappa/Lambda ratio particularly seems to be more sensitive marker than free light chains levels.
